Last update 21 Nov 2024

Interferon alpha-2a biosimilar(Biopartners GmbH)

Last update 21 Nov 2024

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

Drug Type

Interferons, Biosimilar

Synonyms

Alpheon, interferon alfa-2a (Biopartners GmbH), recombinant human interferon alfa-2a (Biopartners GmbH)

Target

IFNAR

Mechanism

IFNAR agonists(Interferon alpha/beta receptor agonists), Immunomodulators, Innate antiviral immune response inducers

Therapeutic Areas

Infectious DiseasesDigestive System Disorders

Active Indication-

Inactive Indication

Hepatitis C, Chronic

Originator Organization

Biopartners GmbH

Active Organization-

Inactive Organization

Biopartners GmbH

Drug Highest PhaseDiscontinuedNDA/BLA

First Approval Date-

Regulation-

Gene Sequence

Sequence Code 32821

The sequence is quoted from: *****

Clinical Trials associated with Interferon alpha-2a biosimilar(Biopartners GmbH)

ChiCTR2100043961 / RecruitingPhase 4IIT

Efficacy and safety of recombinant human interferon a - 2A suppository in patients with cervical HPV infection

Start Date12 Mar 2021

Sponsor / Collaborator

The Second Affiliated Hospital of Xi'an Jiaotong University

100 Clinical Results associated with Interferon alpha-2a biosimilar(Biopartners GmbH)

100 Translational Medicine associated with Interferon alpha-2a biosimilar(Biopartners GmbH)

100 Patents (Medical) associated with Interferon alpha-2a biosimilar(Biopartners GmbH)

Literatures (Medical) associated with Interferon alpha-2a biosimilar(Biopartners GmbH)

01 Jan 2018·AAPS PharmSciTechQ3 · MEDICINE

Calcium Phosphate Particles as Pulmonary Delivery System for Interferon-α in Mice

Q3 · MEDICINE

Article

Author: Block, Timothy ; Mehta, Anand ; Bell, Stephen J D ; Weidner, Jessica M ; Morçöl, Tülin

Systemically administered interferons are rapidly cleared from the circulation thus requiring frequent dosing to maintain the therapeutic levels of circulating interferon. This is particularly problematic for their use in the treatment of chronic diseases. The purpose of this study was to evaluate the potential of proprietary calcium phosphate (CaP) particles to deliver biologically active interferon alpha (IFNα) via the lungs into systemic circulation. Recombinant human IFNα-2a was formulated with proprietary CaP particles. In vitro biological activity of IFNα was assessed for its potential to activate IFN-induced cellular pathways in HEK-Blu-IFN α/β cell cultures. Antiviral activity was evaluated against vesicular stomatitis virus (VSV) infection of HeLa cells. Male BALB/c mice were used to evaluate the absorption of IFNα from CaP-IFNα across the lungs following intratracheal (IT) instillation. Serum IFNα concentrations up to 9 h post-treatment were determined. Data were analyzed to obtain pharmacokinetic (PK) parameters. Data from these studies indicated that IFNα formulated with CaP retains its biological activity, and it is transported into circulation in a dose-dependent manner. PK analysis showed larger than two-fold area under the serum concentration-time curve (AUC) for CaP-IFNα compared to non-formulated IFNα administered IT. The IFNα formulated with CaP had two-fold longer half-life (t1/2) and mean residence time (MRT) relative to IFNα alone administered by injection. Clearance of CaP-IFNα was slower than IFNα administered IM or IT. Relative bioavailability of CaP-IFNα was 1.3-fold of IFNα injection and twofold of IFNα administered IT. Furthermore, inhalation of aerosolized CaP did not indicate any lung toxicity in animals.

30 Apr 2009·New England Journal of MedicineQ1 · MEDICINE

A Step Forward in Therapy for Hepatitis C

Q1 · MEDICINE

Communications

Author: Hoofnagle, Jay H.

The therapy of hepatitis C began almost 25 years ago with a small trial of recombinant human interferon alfa.1 The rationale for using interferon was its broad antiviral effects and the suspicion that it might be active against the still-undiscovered agent of non-A, non-B hepatitis. Indeed, interferon had striking effects, lowering serum aminotransferase levels and, in a proportion of patients, inducing a lasting improvement in serum enzyme levels. Not until the discovery of the hepatitis C virus (HCV) were the effects of interferon understood; treatment resulted in a decrease in HCV RNA levels, which led to a sustained absence of . . .

01 Jun 2004·American Journal of Veterinary ResearchQ3 · AGRICULTURAL & FORESTRY SCIENCE

Evaluation of cytotoxicity and antiviral activity of recombinant human interferon alfa-2a and recombinant human interferon alfa-B/D hybrid against bovine viral diarrhea virus, infectious bovine rhinotracheitis virus, and vesicular stomatitis virus in vitro

Q3 · AGRICULTURAL & FORESTRY SCIENCE

Article

Author: Peek, Simon F. ; Thomas, Chester B. ; Gangemi, David G. ; Bonds, Michael D. ; Schultz, Ronald D.

AbstractObjective—To evaluate cytotoxicity and antiviral activity of recombinant human interferon alfa-2a and recombinant human interferon alfa-B/D hybrid against cytopathic and noncytopathic bovine viral diarrhea virus (BVDV), infectious bovine rhinotracheitis virus (IBRV), and vesicular stomatitis virus (VSV) in vitro.Sample population—Primary bovine testicular cells and Mardin Darby bovine kidney cells.Procedures—To evaluate cytotoxicity, cells were added to serial dilutions of each interferon. To evaluate antiviral activity of each interferon, interferons were serially diluted 1:10, and tissue culture cells were added; virus was then added at 3 time points. Prevention of viral infection by interferon was defined as failure to induce cytopathologic effect for VSV, IBRV, and cytopathic BVDV and failure to detect virus immunohistochemically for cytopathic and noncytopathic BVDV.Results—No evidence of cytotoxicity in either cell line was detected after incubation with interferon alfa- 2a or interferon alfa-B/D. However, reduced growth rates of tissue culture cells were detected for each interferon when undiluted interferon was tested. Comparable and profound antiviral activities against cytopathic and noncytopathic BVDV were evident for each interferon. Interferon alfa-2a and interferon a-B/D had comparable antiviral activities against VSV. Neither interferon had antiviral activity against IBRV.Conclusions and Clinical Relevance—The safety and marked in vitro antiviral activity against noncytopathic BVDV, cytopathic BVDV, and VSV suggest that interferons alfa-2a and alfa-B/D may be useful for treatment of natural disease after infection with these viruses. (Am J Vet Res2004;65:871–874)

100 Deals associated with Interferon alpha-2a biosimilar(Biopartners GmbH)

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	L03AB04	DB00034

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Hepatitis C, Chronic	Phase 2	EU	Biopartners GmbH	28 Jun 2006

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Interferon alpha-2a biosimilar(Biopartners GmbH)

Overview

Basic Info

Gene Sequence

Related

External Link

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation